MedPath

Pharmaceutical Research Unit, Jordan

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:0
Completed:6

Trial Phases

1 Phases

Phase 1:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (100.0%)

COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.

Phase 1
Withdrawn
Conditions
Healthy
First Posted Date
2015-03-23
Last Posted Date
2020-09-18
Lead Sponsor
Pharmaceutical Research Unit, Jordan
Registration Number
NCT02395237
Locations
🇯🇴

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan

Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DYNABAC 250 MG ENTERIC COATED TABLET
First Posted Date
2014-09-11
Last Posted Date
2020-09-18
Lead Sponsor
Pharmaceutical Research Unit, Jordan
Target Recruit Count
48
Registration Number
NCT02237768
Locations
🇯🇴

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan

Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DYNABAC 250 MG ENTERIC COATED TABLET
First Posted Date
2014-09-11
Last Posted Date
2020-09-18
Lead Sponsor
Pharmaceutical Research Unit, Jordan
Target Recruit Count
48
Registration Number
NCT02237807
Locations
🇯🇴

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan

Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DYNABAC 250 MG ENTERIC COATED TABLET
First Posted Date
2014-07-10
Last Posted Date
2014-07-10
Lead Sponsor
Pharmaceutical Research Unit, Jordan
Target Recruit Count
12
Registration Number
NCT02185833
Locations
🇯🇴

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan

Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DYNABAC 250 MG ENTERIC COATED TABLET
First Posted Date
2014-07-10
Last Posted Date
2014-07-10
Lead Sponsor
Pharmaceutical Research Unit, Jordan
Target Recruit Count
12
Registration Number
NCT02185846
Locations
🇯🇴

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.